Across nine studies and 24,228 patients with obesity and type 2 diabetes who first achieved remission, Roux-en-Y gastric bypass (14,554 patients) carried a lower relapse risk than sleeve gastrectomy (9,674 patients): HR 0.67 (95% CI 0.59-0.76) and OR 0.63 (95% CI 0.52-0.76), with low heterogeneity (I² 0-23%). Patients averaged 49.5 years, BMI 47.7 kg/m², and 5.7 years of diabetes. Subgroup, sensitivity, and publication-bias analyses held up.
Remission is not a cure, and this analysis quantifies a point patients rarely hear: a meaningful share relapse, and the operation chosen shifts that odds. Bypass's advantage plausibly reflects its rerouted gut, which amplifies GLP-1 and bile-acid signaling and produces larger, more durable weight loss than sleeve resection, though the abstract doesn't test mechanisms. The consistency across cohorts is reassuring, yet the evidence is mostly retrospective. Surgeons often steer patients with worse metabolic profiles toward bypass, which would bias results against it, but unmeasured selection could cut either way. Weight regain, a key relapse driver, also wasn't separated from procedure type here. Bypass carries higher risks of nutritional deficiency, internal hernia, and reoperation, so a 33% relative relapse reduction must be weighed against those costs rather than treated as a verdict. For adults with long-standing diabetes weighing surgery, this strengthens the case for discussing bypass specifically, and for continued glucose monitoring after remission. Confirmatory rather than paradigm-shifting; randomized long-term data remain needed.